Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor

Abstract Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maja Zakošek Pipan, Sonja Prpar Mihevc, Malan Štrbenc, Urban Košak, Ilija German Ilić, Jurij Trontelj, Simon Žakelj, Stanislav Gobec, Darja Pavlin, Gregor Majdič
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/32c976e38cff4eb89133a4590bc3ef91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32c976e38cff4eb89133a4590bc3ef91
record_format	dspace
spelling	oai:doaj.org-article:32c976e38cff4eb89133a4590bc3ef912021-12-02T17:25:33ZTreatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor10.1038/s41598-021-97404-22045-2322https://doaj.org/article/32c976e38cff4eb89133a4590bc3ef912021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97404-2https://doaj.org/toc/2045-2322Abstract Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.Maja Zakošek PipanSonja Prpar MihevcMalan ŠtrbencUrban KošakIlija German IlićJurij TronteljSimon ŽakeljStanislav GobecDarja PavlinGregor MajdičNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maja Zakošek Pipan Sonja Prpar Mihevc Malan Štrbenc Urban Košak Ilija German Ilić Jurij Trontelj Simon Žakelj Stanislav Gobec Darja Pavlin Gregor Majdič Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
description	Abstract Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.
format	article
author	Maja Zakošek Pipan Sonja Prpar Mihevc Malan Štrbenc Urban Košak Ilija German Ilić Jurij Trontelj Simon Žakelj Stanislav Gobec Darja Pavlin Gregor Majdič
author_facet	Maja Zakošek Pipan Sonja Prpar Mihevc Malan Štrbenc Urban Košak Ilija German Ilić Jurij Trontelj Simon Žakelj Stanislav Gobec Darja Pavlin Gregor Majdič
author_sort	Maja Zakošek Pipan
title	Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_short	Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_full	Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_fullStr	Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_full_unstemmed	Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_sort	treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/32c976e38cff4eb89133a4590bc3ef91
work_keys_str_mv	AT majazakosekpipan treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT sonjaprparmihevc treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT malanstrbenc treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT urbankosak treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT ilijagermanilic treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT jurijtrontelj treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT simonzakelj treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT stanislavgobec treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT darjapavlin treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor AT gregormajdic treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
_version_	1718380899667542016

Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor

Ejemplares similares